BioNano Genomics (BNGO) Earns Buy Rating from Analysts at Maxim Group

Maxim Group started coverage on shares of BioNano Genomics (NASDAQ:BNGO) in a note issued to investors on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.

Shares of NASDAQ:BNGO opened at $6.53 on Tuesday. BioNano Genomics has a 52-week low of $5.51 and a 52-week high of $10.00.

BioNano Genomics Company Profile

BioNano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Read More: What is a Tariff?

The Fly

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply